Bromopride: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Matt Pijoan (talk | contribs)
Bots, Bureaucrats, bureaucrats, Interface administrators, interwiki, nocaptcha, smwadministrator, staff, Administrators, Widget editors
7,579 edits
m Protected "Bromopride": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))
 
Aparna Vuppala (talk | contribs)
nocaptcha, Administrators
6,313 edits
No edit summary
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
__NOTOC__
{{Drugbox
{{drugbox |
| Verifiedfields = changed
| IUPAC_name = 4-amino-5-bromo-''N''-(2-diethylaminoethyl)-<br>2-methoxybenzamide
| verifiedrevid = 459984201
| image = Bromopride.svg
| IUPAC_name = 4-amino-5-bromo-''N''-[2-(diethylamino)ethyl]-2-methoxybenzamide
| image = Bromopride.png
| image2 = Bromopride0.png
 
<!--Clinical data-->
| tradename = 
| Drugs.com = {{drugs.com|international|bromopride}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_CA = <!--                            / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL        / P      / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                  / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration = Oral, [[intramuscular injection|IM]], [[intravenous therapy|IV]]
 
<!--Pharmacokinetic data-->
| bioavailability = 50 to 75% (oral)<br>78% ([[Intramuscular injection|intramuscular]])
| protein_bound = 40%
| metabolism = [[Liver|Hepatic]]
| elimination_half-life = 4 to 5 hours
| excretion = [[Kidney|Renal]], 10 to 14% unchanged
 
<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 4093-35-0
| CAS_number = 4093-35-0
| ATC_prefix = A03
| ATC_prefix = A03
| ATC_suffix = FA04
| ATC_suffix = FA04
| PubChem = 2446
| PubChem = 2446
| DrugBank =  
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| C = 14 | H = 22 | Br = 1 | N = 3 | O = 2
| DrugBank = DB09018
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2352
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 75473V2YZK
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07101
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 399510
 
<!--Chemical data-->
| C=14 | H=22 | Br=1 | N=3 | O=2  
| molecular_weight = 344.248 g/mol
| molecular_weight = 344.248 g/mol
| bioavailability = 50 to 75% (oral)<br>78% ([[Intramuscular injection|intramuscular]])
| smiles = Brc1cc(c(OC)cc1N)C(=O)NCCN(CC)CC
| protein_bound = 40%
| InChI = 1/C14H22BrN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)
| metabolism = [[Liver|Hepatic]]
| InChIKey = GIYAQDDTCWHPPL-UHFFFAOYAA
| elimination_half-life = 4 to 5 hours
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| excretion = [[Kidney|Renal]], 10 to 14% unchanged
| StdInChI = 1S/C14H22BrN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)
| pregnancy_AU =  <!-- A / B1 / B2 / B3 / C / D / X -->
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| pregnancy_US = <!-- A / B            / C / D / X -->
| StdInChIKey = GIYAQDDTCWHPPL-UHFFFAOYSA-N
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_CA =  <!--                             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK =  <!-- GSL        / P      / POM / CD / Class A, B, C -->
| legal_US =  <!-- OTC                  / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status = [[Regulation of therapeutic goods#Brazil|Red Label]] <small>([[Brazil|BR]])</small>
| routes_of_administration = Oral, [[intramuscular injection|IM]], [[intravenous therapy|IV]]
}}
}}
__NOTOC__
{{SI}}
{{CMG}}
==Overview==
'''Bromopride''' ([[International Nonproprietary Name|INN]]) is a [[dopamine antagonist]] with [[prokinetic]] properties widely used as an [[antiemetic]], closely related to [[metoclopramide]]. It is not available in the [[United States]].
'''Bromopride''' ([[International Nonproprietary Name|INN]]) is a [[dopamine antagonist]] with [[prokinetic]] properties widely used as an [[antiemetic]], closely related to [[metoclopramide]]. It is not available in the [[United States]].


Line 30: Line 63:


==Indications==
==Indications==
Bromopride is indicated in the treatment of [[nausea]] and [[vomiting]], including [[postoperative nausea and vomiting]] (PONV); [[gastroesophageal reflux disease]] (GERD/GORD); and as preparation for [[endoscopy]] and [[gastrointestinal series|radiographic studies of the gastrointestinal tract]]. The manufacturer also claims it is valuable in, among other indications, [[hiccups]] and gastrointestinal adverse effects of [[radiation therapy]].  
Bromopride is indicated in the treatment of [[nausea]] and [[vomiting]], including [[postoperative nausea and vomiting]] (PONV); [[gastroesophageal reflux disease]] (GERD/GORD); and as preparation for [[endoscopy]] and [[Upper GI series|radiographic studies of the gastrointestinal tract]]. The manufacturer also claims it is valuable in, among other indications, [[hiccups]] and gastrointestinal adverse effects of [[radiation therapy]].  


==Adverse effects==
==Adverse effects==
Bromopride is generally well tolerated; the most common [[adverse drug reaction|adverse effects]] of its use are [[somnolence]] and fatigue. Bromopride may rarely cause [[extrapyramidal symptoms]] and, as metoclopramide, may increase [[prolactin]] levels.<ref>{{cite web | url = http://bulario.bvs.br/index.php?action=search.2004031716564761099966000112&mode=dir&letter=B | title = Bula do Profissional de Saúde: Bromoprida | date = [[April 11]] [[2006]] | accessdate = 2007-07-23 | publisher = Brazilian National Health Surveillance Agency | work = Bulário Eletrônico da Anvisa | language = Portuguese}}</ref>
Bromopride is generally well tolerated; the most common [[adverse drug reaction|adverse effects]] of its use are [[somnolence]] and fatigue. Bromopride may rarely cause [[extrapyramidal symptoms]] and, as with metoclopramide, may increase [[prolactin]] levels.<ref>{{cite web | url = http://bulario.bvs.br/index.php?action=search.2004031716564761099966000112&mode=dir&letter=B | title = Bula do Profissional de Saúde: Bromoprida | date = April 11, 2006 | accessdate = 2007-07-23 | publisher = Brazilian National Health Surveillance Agency | work = Bulário Eletrônico da Anvisa | language = Portuguese}}</ref>


==Chemistry==
==Chemistry==
Line 39: Line 72:


==Availability==
==Availability==
Bromopride is not available in the United States or the United Kingdom. It is marketed in [[Brazil]] by [[Sanofi-Synthélabo]] under the trade name '''Digesan''' and as a [[generic drug]].
Bromopride is not available in the United States or the United Kingdom. It is marketed in [[Brazil]] by [[Sanofi-Synthélabo]] under the trade name '''Digesan'', by LIBBS under the name Plamet, and as a [[generic drug]].


==References==
==References==
{{Reflist}}
{{Reflist|2}}


{{Propulsives}}


[[Category:Drugs]]
[[Category:Antiemetics]]
{{WikiDoc Help Menu}}
[[Category:Dopamine antagonists]]
{{WikiDoc Sources}}
[[Category:Motility stimulants]]
[[Category:Phenol ethers]]
[[Category:Drug]]

Latest revision as of 14:46, 13 April 2015

Bromopride
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral, IM, IV
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability50 to 75% (oral)
78% (intramuscular)
Protein binding40%
MetabolismHepatic
Elimination half-life4 to 5 hours
ExcretionRenal, 10 to 14% unchanged
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC14H22BrN3O2
Molar mass344.248 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Bromopride

Articles

Most recent articles on Bromopride

Most cited articles on Bromopride

Review articles on Bromopride

Articles on Bromopride in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Bromopride

Images of Bromopride

Photos of Bromopride

Podcasts & MP3s on Bromopride

Videos on Bromopride

Evidence Based Medicine

Cochrane Collaboration on Bromopride

Bandolier on Bromopride

TRIP on Bromopride

Clinical Trials

Ongoing Trials on Bromopride at Clinical Trials.gov

Trial results on Bromopride

Clinical Trials on Bromopride at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Bromopride

NICE Guidance on Bromopride

NHS PRODIGY Guidance

FDA on Bromopride

CDC on Bromopride

Books

Books on Bromopride

News

Bromopride in the news

Be alerted to news on Bromopride

News trends on Bromopride

Commentary

Blogs on Bromopride

Definitions

Definitions of Bromopride

Patient Resources / Community

Patient resources on Bromopride

Discussion groups on Bromopride

Patient Handouts on Bromopride

Directions to Hospitals Treating Bromopride

Risk calculators and risk factors for Bromopride

Healthcare Provider Resources

Symptoms of Bromopride

Causes & Risk Factors for Bromopride

Diagnostic studies for Bromopride

Treatment of Bromopride

Continuing Medical Education (CME)

CME Programs on Bromopride

International

Bromopride en Espanol

Bromopride en Francais

Business

Bromopride in the Marketplace

Patents on Bromopride

Experimental / Informatics

List of terms related to Bromopride

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Bromopride (INN) is a dopamine antagonist with prokinetic properties widely used as an antiemetic, closely related to metoclopramide. It is not available in the United States.

Bromopride appears to be safe and effective for use in pregnancy.[1]

Indications

Bromopride is indicated in the treatment of nausea and vomiting, including postoperative nausea and vomiting (PONV); gastroesophageal reflux disease (GERD/GORD); and as preparation for endoscopy and radiographic studies of the gastrointestinal tract. The manufacturer also claims it is valuable in, among other indications, hiccups and gastrointestinal adverse effects of radiation therapy.

Adverse effects

Bromopride is generally well tolerated; the most common adverse effects of its use are somnolence and fatigue. Bromopride may rarely cause extrapyramidal symptoms and, as with metoclopramide, may increase prolactin levels.[2]

Chemistry

Bromopride is a substituted benzamide, closely related to metoclopramide.[3] It is identical to metoclopramide except for the presence of a bromine atom where metoclopramide has a chlorine substituent.

Availability

Bromopride is not available in the United States or the United Kingdom. It is marketed in Brazil by Sanofi-Synthélabo under the trade name 'Digesan, by LIBBS under the name Plamet, and as a generic drug.

References

  1. ↑ Araújo JR (1981). "Evaluation of bromopride in nausea and vomiting of pregnancy". J Bras Ginecol (in Portuguese). 91 (4): 283–5.
  2. ↑ "Bula do Profissional de Saúde: Bromoprida". Bulário Eletrônico da Anvisa (in Portuguese). Brazilian National Health Surveillance Agency. April 11, 2006. Retrieved 2007-07-23.
  3. ↑ Brodie RR, Chasseaud LF, Darragh A, Lambe RF, Rooney L, Taylor T (1986). "Pharmacokinetics and bioavailability of the anti-emetic agent bromopride". Biopharm Drug Dispos. 7 (3): 215–22. doi:10.1002/bdd.2510070302. PMID 3730521.

Template:Propulsives

Retrieved from "https://www.wikidoc.org/index.php?title=Bromopride&oldid=1086580"